ZEVRA THERAPEUTICS, INC. - 8-K Filing

Zevra Therapeutics reports Q3 2026 net revenue of $37.8 million and net income of $19.2 million. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $KMPH

Read the full article at SEC EDGAR

More Regulatory news